SecBot SecBot
SECBOTREPLAY Home › Report › BWAY

BWAY · BrainsWay announced publication of a peer-reviewed secondary analysis…

Brainsway Ltd. · 6-K filed Aug 27, 2026 at 07:30 ET

At the news

BULLISHIMPACT 6/10

6-K filed Aug 27, 2026 at 07:30 ET

BrainsWay announced publication of a peer-reviewed secondary analysis in the Journal of Affective Disorders showing a 70% relative reduction in suicidal ideation among MDD patients treated with Deep TMS (from 22.5% to 6.7% over 6 weeks). The data adds to a growing body of 2026 research supporting Deep TMS for suicidality, though the device is not FDA-cleared for this indication. The filing is a clinical-data update without financial figures, providing incremental positive evidence for label expansion potential.

  • 70% relative reduction in patients with suicidal ideation (SSI>0) from 22.5% at baseline to 6.7% after 6 weeks of Deep TMS
  • Median time to improvement in suicidality was 10 days with SWIFT accelerated protocol vs 13 days with standard protocol (statistically significant)
  • Data published in Journal of Affective Disorders as secondary analysis of prior multisite randomized trial that supported FDA clearance of SWIFT in September 2025
  • Deep TMS is not FDA-cleared for treatment or prevention of suicidal ideation or behavior

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access